Scholarlink

Purpose <p>The proteasome inhibitor bortezomib and purine nucleoside analog clofarabine combination had greater than additive activity in the NCI-ALMANAC preclinical screen. We conducted a phase 1 trial (NCT02211755) to evaluate the combination’s safety and efficacy in patients.</p> Experimental design <p>We administered bortezomib subcutaneously on days 1 and 4, and clofarabine intravenously on days 1–5 of each 21-day cycle. The primary objective was to establish the safety, tolerability, and maximum tolerated dose (MTD) of bortezomib and clofarabine in patients with refractory solid tumors, lymphomas, or MDS. The secondary objective was to determine the effects of the combination on biomarkers of cell death and DNA damage response (DDR) in tumor biopsies.</p> Results <p>Of 28 patients enrolled, 11 had a best response of stable disease (median 5 cycles; range 2–10 cycles), including 5 patients (4 from the solid tumor cohort, 2 of which were at MTD) with stable disease for ≥ 6 cycles. The MTD for the solid tumor cohort was 1.3 mg/m<sup>2</sup> bortezomib on days 1 and 4, and 1.5 mg/m<sup>2</sup> clofarabine on days 1–5 of each cycle. The MDS cohort closed prior to MTD determination, due to low accrual. The most common study drug related adverse events were hematologic. Two out of 3 patients with evaluable biopsies had increased markers of cell death, and 1 patient also had increased DDR markers after treatment.</p> Conclusion <p>The combination of bortezomib with clofarabine demonstrated limited antitumor effects possibly due to the inability to reach the efficacious doses achieved in preclinical models.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月14日

查看全文
  • Jibran Ahmed,
  • Andre DeSouza,
  • Shivaani Kummar,
  • Lawrence Rubinstein,
  • Geraldine O’Sullivan-Coyne,
  • Jeevan Govindharajulu,
  • William Herrick,
  • Kate Ferry-Galow,
  • Li Li,
  • Deborah F. Wilsker,
  • Murielle Hogu,
  • Richard Piekarz,
  • Robert Meehan,
  • Mohamad Adham Salkeni,
  • Sarah Shin,
  • Brandon Miller,
  • Jennifer Zlott,
  • Lamin Juwara,
  • Karen Gray,
  • Laura Kuhlmann,
  • Apurva Srivastava,
  • Ralph E. Parchment,
  • James H. Doroshow,
  • Naoko Takebe,
  • Alice P. Chen

摘要

Purpose

The proteasome inhibitor bortezomib and purine nucleoside analog clofarabine combination had greater than additive activity in the NCI-ALMANAC preclinical screen. We conducted a phase 1 trial (NCT02211755) to evaluate the combination’s safety and efficacy in patients.

Experimental design

We administered bortezomib subcutaneously on days 1 and 4, and clofarabine intravenously on days 1–5 of each 21-day cycle. The primary objective was to establish the safety, tolerability, and maximum tolerated dose (MTD) of bortezomib and clofarabine in patients with refractory solid tumors, lymphomas, or MDS. The secondary objective was to determine the effects of the combination on biomarkers of cell death and DNA damage response (DDR) in tumor biopsies.

Results

Of 28 patients enrolled, 11 had a best response of stable disease (median 5 cycles; range 2–10 cycles), including 5 patients (4 from the solid tumor cohort, 2 of which were at MTD) with stable disease for ≥ 6 cycles. The MTD for the solid tumor cohort was 1.3 mg/m2 bortezomib on days 1 and 4, and 1.5 mg/m2 clofarabine on days 1–5 of each cycle. The MDS cohort closed prior to MTD determination, due to low accrual. The most common study drug related adverse events were hematologic. Two out of 3 patients with evaluable biopsies had increased markers of cell death, and 1 patient also had increased DDR markers after treatment.

Conclusion

The combination of bortezomib with clofarabine demonstrated limited antitumor effects possibly due to the inability to reach the efficacious doses achieved in preclinical models.